Lucarista / Shutterstock.com
A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis (MS) drug Gileyna (fingolimod).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Gileyna, fingolimod, multiple sclerosis, RRMS, MS, Mylan, Dr. Reddys, Teva, injunction